Histone Modification Pathways in Neurodegeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders. [1]
Histone modifications represent a fundamental mechanism of epigenetic regulation, controlling gene expression through chemical modifications to histone proteins around which DNA is wrapped. These post-translational modifications—including acetylation, methylation, phosphorylation, ubiquitination, and sumoylation—form the "histone code" that regulates chromatin accessibility and transcriptional programs. Dysregulation of histone modifying enzymes has emerged as a key contributor to neurodegenerative disease pathogenesis, with evidence accumulating for altered histone acetylation, methylation, and other modifications in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and frontotemporal dementia (FTD). Understanding these epigenetic changes provides not only mechanistic insights but also therapeutic opportunities through pharmacologic manipulation of histone-modifying enzymes. [2]
The basic unit of chromatin is the nucleosome, consisting of approximately 147 base pairs of DNA wrapped around an octamer of histone proteins: two copies each of H2A, H2B, H3, and H4. The N-terminal tails of these histone proteins extend outward from the nucleosome core and are subject to numerous post-translational modifications that influence chromatin structure 1. These tails contain lysine and arginine residues that can be acetylated, methylated, phosphorylated, or ubiquitinated, creating a combinatorial code that determines transcriptional outcomes. [3]
The histone octamer forms a protein core around which DNA wraps approximately 1.65 turns, creating ~147 bp of contact. This packaging compacts the genome but also creates a barrier to transcription factors and polymerases. The histone modifications discussed on this page dynamically regulate this accessibility. [4]
Key histone residues and their modifications: [5]
| Histone | Residue | Modification | Function | [6]
|---------|---------|--------------|----------| [7]
| H3 | K4 | Trimethylation | Active transcription | [8]
| H3 | K9 | Trimethylation | Gene silencing | [9]
| H3 | K27 | Trimethylation | Polycomb repression | [10]
| H3 | K36 | Trimethylation | Transcription elongation | [11]
| H3 | K79 | Trimethylation | Transcription regulation | [12]
| H3 | S10 | Phosphorylation | Mitotic chromosome condensation | [13]
| H4 | K16 | Acetylation | Chromatin decompaction | [14]
| H4 | K20 | Trimethylation | DNA damage response | [15]
Acetylation: Addition of acetyl groups to lysine residues (primarily on H3 and H4 tails). Neutralizes positive charge, weakening histone-DNA interactions and promoting transcriptional activation. Regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs). [16]
Methylation: Addition of methyl groups to lysine or arginine residues. Can be mono-, di-, or trimethylated. Lysine methylation is typically associated with either activation (H3K4me3, H3K36me3) or repression (H3K9me3, H3K27me3) depending on the residue modified. Arginine methylation can be symmetric or asymmetric, with distinct functional consequences. [17]
Phosphorylation: Addition of phosphate groups to serine, threonine, or tyrosine residues. Often associated with transcriptional activation, cell cycle regulation, or DNA damage response. The highly conserved H3S10 phosphorylation is one of the best-characterized histone phosphorylation marks. [18]
Ubiquitination: Addition of ubiquitin to lysine residues. H2A and H2B ubiquitination regulate transcription and DNA repair. Monoubiquitination typically activates transcription, while polyubiquitination can target histones for degradation. [19]
Sumoylation: Similar to ubiquitination but with SUMO proteins. Generally represses transcription through multiple mechanisms including blocking other modifications and recruiting repressive complexes. [20]
Crotonylation: A newer modification linked to active transcription in testis and possibly brain. This modification may regulate sex chromosome-associated genes and has been detected in brain tissue. [21]
Histone deacetylases (HDACs) are subdivided into four classes based on homology and function: [22]
Multiple lines of evidence implicate HDAC dysregulation in neurodegenerative diseases: [23]
The first evidence linking HDACs to AD came from studies showing that HDAC2 is elevated in AD brain and correlates with memory impairment. HDAC2 is recruited to memory-related genes including Bdnf, Creb, and c-fos, repressing their expression 2. Key findings include: [24]
Additional HDAC changes in AD include: [25]
HDAC inhibitors improve memory in AD mouse models through multiple mechanisms: [26]
PD shows characteristic changes in histone acetylation: [27]
SIRT2 is of particular interest in PD: [28]
ALS shows dysregulation of multiple HDAC classes: [29]
The role of specific HDACs in ALS: [30]
HD is characterized by transcriptional dysfunction, and HDACs play central roles:
HDAC inhibitor studies in HD:
Histone acetyltransferases (HATs) including CBP (CREB-binding protein), p300, and GCN5 are equally important:
CBP/p300 functions:
Therapeutic approaches targeting HATs:
Histone methylation is dynamically regulated by lysine methyltransferases (KMTs) and lysine demethylases (KDMs). These enzymes add or remove methyl groups from specific histone residues, with distinct consequences for gene expression depending on the modified site.
Multiple histone methylation changes occur in AD:
Specific findings in AD:
KDM inhibitors in development:
PD shows specific histone methylation changes:
The G9a pathway in PD:
ALS and FTD show distinctive histone methylation changes:
TDP-43 and histone methylation:
Histone methylation interacts with DNA methylation to regulate gene expression:
Phosphorylation of histone H3 at serine 10 (H3S10ph) is associated with mitosis and transcriptional activation:
γH2AX forms at DNA double-strand breaks:
H2A ubiquitination (H2Aub) is a repressive mark:
H2B ubiquitination (H2Bub) is associated with transcription elongation:
Multiple HDAC inhibitors have been tested or are in development for neurodegenerative diseases:
| Drug | Class | Target Disease | Status |
|---|---|---|---|
| Valproic acid | Class I/II | AD, HD | Phase II trials |
| Vorinostat | Class I | HD | Approved for cancer |
| Sodium butyrate | Class I/II | HD | Preclinical |
| Entinostat (MS-275) | Class I | AD | Phase II |
| Ricolinostat (ACY-1215) | Class I/II | ALS | Phase I/II |
| SRT2104 (Sirtuin activator) | SIRT1 | AD | Phase I |
| Pracinostat | Class I/II | ALS | Preclinical |
Isoform-selective inhibitors: Developing inhibitors specific for:
Targeting specific KMTs/KDMs:
Epigenetic editing: Using CRISPR-dCas9 fusions to recruit histone modifiers to specific gene promoters
Combination therapy: HDAC inhibitors with:
The histone code provides a fundamental mechanism for regulating gene expression in the brain, and its dysregulation contributes to neurodegenerative disease pathogenesis. Altered histone acetylation, methylation, phosphorylation, and ubiquitination have been documented in AD, PD, ALS, HD, and FTD, affecting synaptic plasticity genes, oxidative stress responses, protein homeostasis, and neuroinflammation. While HDAC inhibitors have shown promise in preclinical models, translation to clinical therapy faces challenges of selectivity, penetration, and side effects. Future directions include developing more selective epigenetic drugs, combination approaches, and epigenetic editing technologies. Understanding the epigenetic basis of neurodegeneration offers not only mechanistic insights but also a promising avenue for therapeutic intervention in these devastating diseases.
Histone variants are non-allelic variants of the core histones that replace canonical histones in specific contexts:
Specific histone variant changes in neurodegenerative diseases:
H2A.Z in AD:
H3.3 in ALS:
H2A.Bbd in aging:
Beyond histone modifications, ATP-dependent remodeling complexes dynamically regulate chromatin:
Chromatin remodeling dysfunction in disease:
SWI/SNF in neurodevelopment:
INO80 in aging:
Newer inhibitors show improved selectivity:
| Inhibitor | Selectivity | Clinical Status |
|---|---|---|
| Entinostat (MS-275) | Class I | Phase II for AD |
| Ricolinostat | HDAC6 | Phase I/II for ALS |
| ACY-738 | HDAC6 | Preclinical |
| Nexturastat A | HDAC6 | Preclinical |
More selective inhibitors in development:
EZH2 inhibitors are in cancer trials and being explored for neurodegeneration:
G9a inhibition shows promise:
LSD1 inhibitors in development:
KDM5 (JARID1) family inhibitors:
Bromodomains "read" histone acetylation:
Chromodomains "read" histone methylation:
| Target | Inhibitor Class | Disease Focus |
|---|---|---|
| BET family | BET inhibitors | AD, HD |
| BRD4 | BRD4 inhibitors | ALS |
| CHD1 | CHD1 activators | Cognitive enhancement |
Using CRISPR for epigenetic therapy:
Measuring treatment effects:
Target engagement markers:
Optimizing trial populations:
Clinical trial considerations:
Rationale for combinations:
Landles C et al. Pathogenesis of Huntington's disease (2020). 2020. ↩︎
Johnson R et al. Epigenetic therapy for neurodegenerative disease (2019). 2019. ↩︎
Coppedè F et al. Epigenetics in Alzheimer's disease (2019). 2019. ↩︎
Liu L et al. Histone acetylation in ALS (2021). 2021. ↩︎
Benito E et al. HDAC2 and memory (2018). 2018. ↩︎
Duan W et al. Targeting epigenetics in AD (2020). 2020. ↩︎
Jin Y et al. SIRT1 and neuroprotection (2019). 2019. ↩︎
Gray SG et al. HDAC inhibitors in neurodegenerative disease (2019). 2019. ↩︎
Koch P et al. Histone modifications and cognitive function (2021). 2021. ↩︎
Stilling RM et al. Epigenetic regulation of memory (2019). 2019. ↩︎
Morrison BE et al. Chromatin remodeling in neurodegeneration (2019). 2019. ↩︎
Rando OJ et al. Histone variants in brain function (2020). 2020. ↩︎
Chen T et al. Epigenetic editing technologies (2021). 2021. ↩︎
Sanchez GJ et al. BET inhibitors in neurological disease (2019). 2019. ↩︎
Knutson SK et al. EZH2 inhibition in disease (2020). 2020. ↩︎
Holemon H et al. G9a inhibitors in cognitive disorders (2020). 2020. ↩︎
Korzus E et al. Chromatin remodeling and memory (2019). 2019. ↩︎
Tsai L et al. Histone acetylation dynamics in brain (2020). 2020. ↩︎
Mahmoud SA et al. Histone modifications in aging brain (2021). 2021. ↩︎
Day JJ et al. DNA methylation and memory (2019). 2019. ↩︎
Penney J et al. Epigenetics of Alzheimer's disease (2020). 2020. ↩︎
Sanchez-Mut JV et al. Epigenetic landscapes in neurodegeneration (2020). 2020. ↩︎
Graff J et al. Cognitive enhancers via epigenetics (2019). 2019. ↩︎
Gomez GL et al. Histone deacetylases in PD (2020). 2020. ↩︎
St Laurent R et al. Sirtuins and mitochondrial function (2019). 2019. ↩︎
Hirano Y et al. Chromatin and neuronal plasticity (2020). 2020. ↩︎
Fukuda K et al. Epigenetic interventions in stroke (2021). 2021. ↩︎
Ball AS et al. HDAC therapy in Rett syndrome (2020). 2020. ↩︎
Tammen SA et al. SAM-dependent methyltransferases in disease (2019). 2019. ↩︎
Kennedy PJ et al. Class I HDAC inhibitors in brain (2020). 2020. ↩︎